Published in World J Surg on May 13, 2003
Diagnostic and surgical approaches in hilar cholangiocarcinoma. Int J Colorectal Dis (2006) 0.85
Surgical palliation for unresectable hilar cholangiocarcinoma. HPB (Oxford) (2005) 0.75
Predictors of long term survival after hepatic resection for hilar cholangiocarcinoma: A retrospective study of 5-year survivors. World J Gastrointest Surg (2016) 0.75
ADENOCARCINOMA OF THE HEPATIC DUCT AT ITS BIFURCATION WITHIN THE PORTA HEPATIS. AN UNUSUAL TUMOR WITH DISTINCTIVE CLINICAL AND PATHOLOGICAL FEATURES. Am J Med (1965) 4.22
Management strategies in resection for hilar cholangiocarcinoma. Ann Surg (1992) 3.69
Extended resections for hilar cholangiocarcinoma. Ann Surg (1999) 2.93
Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg (1998) 2.81
Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg (1996) 2.54
Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg (1996) 2.35
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Proximal bile duct cancer: high resectability rate and 5-year survival. Ann Surg (1999) 1.83
Sclerosing carcinoma of the major intrahepatic bile ducts. AMA Arch Surg (1957) 1.82
Carcinoma of the main hepatic duct junction: indications, operative morbidity and mortality, and long-term survival. Surgery (1990) 1.79
Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded). Results of the French Surgical Association Survey. Ann Surg (1991) 1.75
Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg (2000) 1.71
Incidence of benign lesions in patients resected for suspicious hilar obstruction. Br J Surg (2001) 1.62
Aggressive surgical therapy for Klatskin tumors. Am J Surg (1993) 1.60
Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg (2000) 1.57
Proximal bile duct cancer. Quality of survival. Ann Surg (1987) 1.54
Surgical treatment of hilar carcinoma of the bile duct. Surg Gynecol Obstet (1986) 1.49
Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer (1977) 1.49
Clinicopathologic factors influencing survival of patients with bile duct carcinoma: multivariate statistical analysis. World J Surg (1994) 1.33
Differential diagnosis of sclerosing cholangiocarcinomas of the common hepatic duct (Klatskin tumors). Am J Surg (1991) 1.26
Benign fibrosing disease at the hepatic confluence mimicking Klatskin tumors. Surgery (1992) 1.11
Carcinoma of the extrahepatic bile duct: mode of spread and its prognostic implications. Hepatogastroenterology (1997) 1.00
Resection and bypass for malignant obstruction of the bile duct. World J Surg (1995) 0.82
Surgical strategy for the management of hilar bile duct cancer. Br J Surg (1997) 0.80
Orthotopic liver transplantation after extended bile duct resection as treatment of hilar cholangiocarcinoma. First long-terms results. Transpl Int (1998) 0.78
Neoplasm of the hepatic hilum: the role of resection. Hepatogastroenterology (1993) 0.77
Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med (2014) 6.10
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol (2009) 5.57
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology (2014) 4.00
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol (2008) 3.09
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol (2013) 2.94
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol (2010) 2.36
EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res (2009) 2.30
Use of a peripheral venous catheter in single-incision laparoscopic surgery. Surg Endosc (2010) 2.04
Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun (2007) 1.87
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol (2010) 1.80
Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. Atherosclerosis (2009) 1.78
Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol (2011) 1.78
T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood (2002) 1.71
Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2003) 1.64
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer (2007) 1.58
12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl (2006) 1.53
Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test. Arch Pathol Lab Med (2012) 1.53
Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transpl Int (2012) 1.50
Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant (2005) 1.50
Chlamydia psittaci Infection in nongastrointestinal extranodal MALT lymphomas and their precursor lesions. Am J Clin Pathol (2011) 1.49
Current value of intraoperative sonography during surgery for hepatic neoplasms. World J Surg (2002) 1.48
Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol (2012) 1.44
Accuracy of multiphasic helical computed tomography and intraoperative sonography in patients undergoing orthotopic liver transplantation for hepatoma: what is the truth? Ann Surg (2002) 1.44
90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma. Leuk Lymphoma (2010) 1.43
Comparison between C0 and C2 monitoring in de novo renal transplant recipients: retrospective analysis of a single-center experience. Transplantation (2004) 1.43
Vienna experience of ABO-incompatible living-donor kidney transplantation. Wien Klin Wochenschr (2009) 1.42
Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with fludarabine: effect on tumor microenvironment. Leuk Lymphoma (2011) 1.42
Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol (2011) 1.41
Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol (2008) 1.39
High-risk human papilloma virus infection of the foreskin in asymptomatic boys. Urology (2013) 1.39
c-kit overexpression in chromophobe renal cell carcinoma is not associated with c-kit mutation of exons 9 and 11. Am J Surg Pathol (2005) 1.39
Genetic association study identifies HSPB7 as a risk gene for idiopathic dilated cardiomyopathy. PLoS Genet (2010) 1.37
LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology (2005) 1.37
Impaired tubulointerstitial expression of endothelin-1 and nitric oxide isoforms in donor kidney biopsies with postischemic acute renal failure. Transplantation (2003) 1.37
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol (2010) 1.36
The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res (2002) 1.35
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol (2010) 1.32
Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol (2010) 1.31
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood (2004) 1.30
Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol (2006) 1.30
Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation (2007) 1.29
Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med (2011) 1.28
Hepatocellular carcinoma--survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int (2005) 1.28
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer (2008) 1.26
Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointest Surg (2002) 1.26
Prognostic scoring in colorectal cancer liver metastases: development and validation. Arch Surg (2005) 1.26
Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin Cancer Res (2008) 1.25
Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival? Transpl Int (2006) 1.25
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica (2012) 1.25
High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood (2002) 1.22
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest (2003) 1.21
Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. Anticancer Res (2007) 1.21
Surgery for gastrointestinal stromal tumors of the stomach. J Gastrointest Surg (2009) 1.18
Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood (2002) 1.17
Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. Clin Gastroenterol Hepatol (2005) 1.17
Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol (2011) 1.17
Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol (2010) 1.16
Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica (2008) 1.14
Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med (2004) 1.12
Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood (2002) 1.12
Perivascular cells expressing annexin A5 define a novel mesenchymal stem cell-like population with the capacity to differentiate into multiple mesenchymal lineages. Development (2005) 1.11
Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol (2010) 1.10
High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab (2010) 1.10
Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin Cancer Res (2004) 1.09
Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts. PLoS One (2012) 1.09
Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med (2005) 1.07
Positron emission tomography with [18F] 2-fluoro-D-2- deoxyglucose in primary cutaneous T-cell lymphomas. Haematologica (2004) 1.07
Underlying autoimmune diseases are not aggravated during treatment with lenalidomide in patients with mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma (2014) 1.07
Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. Dtsch Arztebl Int (2008) 1.07
A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica (2012) 1.07
Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.07
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology (2011) 1.04
Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res (2007) 1.04
Interactions of LSECtin and DC-SIGN/DC-SIGNR with viral ligands: Differential pH dependence, internalization and virion binding. Virology (2008) 1.04
Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res (2007) 1.02
Patient and graft survival in older kidney transplant recipients: does age matter? J Am Soc Nephrol (2004) 1.02
Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol (2002) 1.02
Genome-wide gene-expression patterns of donor kidney biopsies distinguish primary allograft function. Lab Invest (2004) 1.01
KiSS-1 overexpression as an independent prognostic marker in hepatocellular carcinoma: an immunohistochemical study. Virchows Arch (2007) 1.01
MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1. Clin Cancer Res (2012) 1.00
Thromboembolic events during treatment with thalidomide. Blood (2002) 1.00
Mosaicism due to myeloid lineage restricted loss of heterozygosity as cause of spontaneous Rh phenotype splitting. Blood (2007) 1.00